Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU (REVISE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02290327|
Recruitment Status : Completed
First Posted : November 14, 2014
Last Update Posted : February 8, 2016
|Condition or disease||Intervention/treatment||Phase|
|Stress Ulcer Prophylaxis||Drug: Pantoprazole Drug: Placebo||Phase 3|
Background For almost 4 decades, stress ulcer prophylaxis to prevent upper gastrointestinal (GI) bleeding has been standard of care in the ICU. The 1999 American Society of Health-System Pharmacists guidelines recommend stress ulcer prophylaxis for the critically ill. The 2013 Surviving Sepsis Campaign guidelines recommend stress ulcer prophylaxis for patients mechanically ventilated for > 48 hours or with coagulopathy. However, GI bleeding rates are significantly lower today than in the past, potentially reduced by optimal resuscitation and early enteral nutrition. Additional concerns include whether acid suppression has any impact on bleeding at all, and whether acid suppression does more harm than good, given the apparent increased risk of more common, serious problems of pneumonia and Clostridium difficile infection. Further, prophylaxis has become almost universal rather than targetted at patients at risk of GI bleeding. Thus, clinicians and investigators globally are calling for a re-evaluation of acid suppression with a large Randomized controlled trial (RCT) comparing proton pump inhibitor against placebo.
Objectives To determine the feasibility of performing a large RCT to investigate whether intravenously administered pantoprazole, compared to placebo prevents clinically important gastrointestinal bleeding in mechanically ventilated patients in the intensive care unit (ICU), based on 3 outcomes: the informed consent rate; recruitment rate, and protocol adherence
Design Prospective, concealed, stratified, randomized, blinded, multicentre trial.
Setting Canadian and Saudi medical-surgical university-affiliated ICUs.
Methods Patients will be stratified by center, and medical/surgical/trauma status, then will be randomized to intervention or placebo using an allocation ratio of 1:1 and undisclosed variable block sizes. Research pharmacists will prepare identical 100ml mini-bags of the pantoprazole 40mg or placebo with blinded research labels for once daily dosing.
Followup Research Coordinators in the ICU will review all patients daily, where most of the trial data will be collected. This will involve baseline data (e.g., demographics, illness severity, advanced life support), and daily data (e.g., study medication administered and reasons why not administered), other relevant medications and co-interventions that might influence bleeding, ventilator associated pneumonia (VAP) or Clostridium difficile outcomes (e.g., enteral nutrition, antibiotics, anticoagulants, possible VAP prevention strategies including probiotics), laboratory, microbiology, transfusion or radiology documentation to help adjudicate the outcomes of clinically important and overt bleeding, VAP, and Clostridium difficile infection, and mortality. We do not anticipate any loss to follow up; we expect to have complete follow up of patients in the ICU.
Patients will be followed for primary and secondary outcomes during their ICU stay on daily basis. Once patients are discharged from the ICU, they will no longer be followed daily; only duration of hospital stay and vital status at hospital discharge will be obtained.
A secure web-based central randomization method will ensure site-specific stratified allocation tables. When the patient is identified as eligible and consent is obtained by Research Coordinator, the Research Pharmacist will take the assignment and dispense study drug accordingly.
Relevance Results of the REVISE Pilot Trial will provide key feasibility and safety data which will serve to plan a larger multicentre trial of pantoprazole versus placebo for stress ulcer prophylaxis in mechanically ventilated critically ill patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||91 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Study Start Date :||May 2015|
|Actual Primary Completion Date :||January 2016|
Placebo Comparator: Placebo
50 ml of 0.9% Normal Saline Intravenously once daily
50 ml of 0.9% normal saline
Active Comparator: Pantoprazole
Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
Proton pump inhibitor
- Consent Rate [ Time Frame: 12 months ]
This will be calculated as the overall proportion of consented patients of those substitute decision makers (SDMs) approached (with 95% CI).
A successful consent rate will be defined as ≥70% of SDMs approached to consent.
- Recruitment Rate [ Time Frame: 12 months ]A successful recruitment rate will be defined as achieving enrolment of 90 patients, conventionally expressed as 2 patients per center per month over 12 months.
- Protocol Adherence [ Time Frame: 12 months ]
This will be calculated as doses of study drug administered as a proportion of doses prescribed and associated 95% confidence intervals.
A successful adherence will be defined as ≥80% of prescribed drugs being administered.
- Clinically important upper gastrointestinal bleeding [ Time Frame: During ICU stay (expected average is 10 days) ]
- Ventilator associated pneumonia [ Time Frame: During ICU stay (expected average is 10 days) ]
- Mortality [ Time Frame: During ICU and hospital stay (expected average ICU stay is 10 days, expected average hospital stay is 30 days) ]
- Clostridium Difficile infection [ Time Frame: During ICU stay (expected average ICU stay is 10 days) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02290327
|Canada, Nova Scotia|
|Queen Elizabeth II|
|Halifax, Nova Scotia, Canada|
|St. Joseph's HealthCare Hospital|
|Hamilton, Ontario, Canada, L9K 1N3|
|Hamilton, Ontario, Canada|
|Kingston General Hospital|
|Kingston, Ontario, Canada|
|Ottawa Civic Hospital|
|Ottawa, Ontario, Canada|
|Ottawa General Hospital|
|Ottawa, Ontario, Canada|
|Mount Sinai Hospital|
|Toronto, Ontario, Canada|
|St Michael's Hospital|
|Toronto, Ontario, Canada|
|Dammam, Eastern Province, Saudi Arabia|
|Principal Investigator:||Waleed Alhazzani, MD,FRCPC,MSc||McMaster University|